PPARA and metabolic dysfunction-associated steatohepatitis: Much more complex alterations in the gut microbiome of NASH patients have been reported [125,134], but it is clear that PPAR-targeted therapy might not be effective in the long-term for these patients, since the real cause of the disease is not targeted.